Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06595615
Enrolling by invitation Observational

Health App Data Collection Study

NCT06595615 · tracked via the Priya Life Science USA tracker
Sponsor
Abbott Medical Devices
Phase
Observational
Started
2025-04-09
Last updated
2026-04-03

Condition(s) studied

Cardiac Disease

Investigational drug(s) / intervention(s)

cardiovascular implantable electronic devices

cardiovascular implantable electronic devices: Standard of care patients indicated for the devices

Study summary

Utilization of additional wearable data to improve clinical outcome

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients are willing to be compliant with daily measurements required 18 years of age or older * Patients who have been implanted with ABT CRT-D devices connected to Merlin.net * Patients who had at least one HF clinical event during past 12 calendar months * Must provide written informed consent prior to the commencement of this clinical feasibility study * Patients are willing to be compliant with daily measurements required Exclusion Criteria: * Pregnant and/or lactating mothers will be excluded from the study or have a plan to be pregnant in the next 12 months * Patients with a life expectancy less than the duration of the study, as per clinician's discretion. * Patients who will not be able to complete the daily survey questions due to inability to read

Primary outcome measure(s)

  • Acquisition of additional health data using patient App — 12 months
    Health data acquisition via an app from multiple wearables and externals.

Trial sites (1)

FacilityCityRegionStatus
Heart Center Research Huntsville Alabama

More Abbott Medical Devices trials in the USA

Agilis RF TSP Early Feasibility Study Recruiting
Abbott Structural Heart Device Registry Recruiting
Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator Recruiting
Esprit BTK Post-Approval Study Active, not recruiting
SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy Active, not recruiting

Other trials for the same condition

Kosmos Guidance Performance Evaluation Data Annotation Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06595615 on ClinicalTrials.gov ↗ ← All trials in the USA